NDASUBCUTANEOUSINJECTABLE
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
8
Data completeness
4/8 — Partial
SUMAVEL DOSEPRO (sumatriptan succinate) by Antares Therapeutics is 5-ht 1b/1d receptors. First approved in 2009.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUMAVEL DOSEPRO is a subcutaneous injectable formulation of sumatriptan succinate, a selective 5-HT1B/1D receptor agonist approved in 2009 for acute migraine treatment. It works by constricting intracranial blood vessels and inhibiting pro-inflammatory neuropeptide release via the trigeminal system. The product is delivered via a pre-filled autoinjector device designed for patient self-administration.
LOE Approaching5mo to LOE
As LOE approaches within 5 months, the brand team will shift from growth initiatives to generic transition planning and managed decline strategies, with smaller team sizes in sales and marketing.
Mechanism of Action
5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine
Started Nov 2009
246 enrolled
Migraine
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
Started May 2008
30 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Started Dec 2006
169 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Started Nov 2006
173 enrolled
Migraine Disorders
Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan
Started Jun 2006
75 enrolled
Migraine Disorders
Worked on SUMAVEL DOSEPRO at Antares Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.